Document resource
Introduction Mechanical thrombectomy for the treatment of acute ischemic stroke has undergone relevant technical improvements over the last years. However, distal emboli and incomplete reperfusion after mechanical thrombectomy, are still shortcomings in endovascular acute ischemic stroke care. The NeVa NET 5.5 thrombectomy device (Vesalio, Nashville, Tennessee) is the first stent retriever featuring an integrated clot micro-filtration system; aiming to enhance first pass efficacy and reduce distal embolization.Aim of Study This study evaluates the safety and efficacy of the NeVa NET 5.5 thrombectomy device.Method Patients with acute anterior circulation occlusions and vessel diameters >2 mm treated with the NeVa NET 5.5 stent retriever as a first-line approach, were retrospectively included in this study. Data was collected from three European comprehensive stroke centers between October 2022 and April 2024. Patient data, occlusion details, clinical outcomes, and procedure-related parameters were analyzed.Results A total of 51 patients were included. The most common occlusion locations were the internal carotid artery terminus and intradural internal carotid artery (70.6%). The mean clot length was 25.1 mm ±13.3 (4–50). First-pass reperfusion (eTICI 2b-3) was achieved in 78.5%, with a final reperfusion rate of eTICI 2b-3 in 98.1%. Distal embolization in new territories occurred in 3.9%. No device-related adverse events were reported, and procedure-related adverse events occurred in 7.6% of the overall included cases.Conclusion The NeVa NET 5.5 stent retriever demonstrates high first-pass reperfusion rates in large vessel occlusions of the anterior circulation, with a good safety profile, and low rate of distal embolization.Conflict of Interest Yes BD: has received honoraria as a speaker and consulting fees of Stryker, Acandis, Balt, Phenox and Vesalio; RS: has received honoraria as a speaker and consulting fees for Infinity Neuro, Acandis, Stryker and Vesalio. No disclosures or competing interests were declared by the remaining authors. PJAR : RFA – Research funding for appointed full professors of the Paracelsus Medical University (PMU), Salzburg, Austria (RFA-24–05-Pfaff)